H.C. Wainwright raised the firm’s price target on Relay Therapeutics (RLAY) to $19 from $14 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q4 report to to reflect lower long-term operating expenses.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target raised to $17 from $15 at Citizens
- Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data
- Relay Therapeutics announces data from Phase 1/2 ReDiscover trial
- Relay Therapeutics price target raised to $22 from $15 at Guggenheim
- Relay Therapeutics Updates Bylaws on Federal Securities Litigation